Shire claims a blockbuster in Vyvanse
This article was originally published in Scrip
Shire can finally claim a blockbuster in Vyvanse (lisdexamfetamine), as it reported sales for its new ADHD treatment in 2012 of $1.03 billion, up 28% on the previous year. Further growth seems assured following EU approval in December. In addition, Phase III are trials ongoing with Vyvanse in major depressive disorder, binge eating disorder and negative symptoms of schizophrenia (scripintelligence.com, 16 January 2013). Total sales at Shire for 2012 were up 12% to $4.41 billion.